Immucor Overview
- Year Founded
-
1982
- Status
-
Acquired/Merged
- Employees
-
1,125
- Latest Deal Type
-
M&A
- Financing Rounds
-
15
- Investments
-
6
Immucor General Information
Description
Manufacturer of transfusion and transplantation diagnostic products designed to provide the right match for patients who are in need of blood or an organ. The company offers a complete line of serology-based reagents and instruments used by hospitals, reference labs and donor centers to perform pre-transfusion typing and screening of blood and also renders blood bank software solutions that are designed specifically to enhance the productivity of blood bank laboratories, providing transfusion test results in an efficient and productive way to the customers.
Contact Information
Website
www.immucor.com(Operating Subsidiary)
Corporate Office
- Post Office Box 5625
- Norcross, GA 30091-5625
- United States
Corporate Office
- Post Office Box 5625
- Norcross, GA 30091-5625
- United States
Immucor Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Immucor Comparisons
Industry
Financing
Details
Immucor Competitors (14)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| DexCom | Formerly VC-backed | San Diego, CA | ||||
| Biotronik | Corporate Backed or Acquired | Berlin, Germany | ||||
| ELITechGroup | Formerly PE-Backed | Puteaux, France | ||||
| Genalyte | Venture Capital-Backed | San Diego, CA | ||||
| Baxter International | Corporation | Deerfield, IL |
Immucor Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Immucor Patents
Immucor Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200191806-A1 | Red cell diluent with edta and methods for making and using the same | Active | 03-Apr-2017 | ||
| US-20230375574-A1 | Red cell diluent with chelating agent and methods for making and using the same | Pending | 03-Apr-2017 | ||
| US-11754574-B2 | Red cell diluent with edta and methods for making and using the same | Active | 03-Apr-2017 | ||
| US-20220120739-A1 | Chips, detectors, and methods of making and using the same | Inactive | 20-Jul-2015 | ||
| US-11169150-B2 | Chips, detectors, and methods of making and using the same | Active | 20-Jul-2015 | G01N33/543 |
Immucor Executive Team (13)
| Name | Title | Board Seat |
|---|---|---|
| Avi Pelossof | Chief Executive Officer & President | |
| Dominique Petitgenet | Vice President, Chief Financial Officer and Chief Operating Officer | |
| Margaret Taylor | Chief Administrative Officer | |
| Christina Otis | Chief Marketing Officer & Vice President | |
| Sukanta Banerjee Ph.D | Chief Technology Officer, Vice President and Research & Development |
Immucor Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Self | Board Member |
Immucor Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Immucor Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Immucor Investments & Acquisitions (6)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sirona Genomics | 04-Mar-2016 | Biotechnology | |||
| Sentilus | 01-Oct-2014 | Biotechnology | |||
| Organ-i | 06-Jun-2014 | Biotechnology | |||
| Hologic (LIFECODES business) | 25-Mar-2013 | Diagnostic Equipment | |||
| BioArray Solutions | 05-Aug-2008 | Merger/Acquisition | Application Specific Semiconductors |
Immucor ESG
Risk Overview
Risk Rating
Updated June, 17, 2020
22.63 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,707
Rank
Percentile
Healthcare
Industry
of 545
Rank
Percentile
Medical Devices
Subindustry
of 58
Rank
Percentile
Immucor FAQs
-
When was Immucor founded?
Immucor was founded in 1982.
-
Who is the CEO of Immucor?
Avi Pelossof is the CEO of Immucor.
-
Where is Immucor headquartered?
Immucor is headquartered in Norcross, GA.
-
What is the size of Immucor?
Immucor has 1,125 total employees.
-
What industry is Immucor in?
Immucor’s primary industry is Diagnostic Equipment.
-
Is Immucor a private or public company?
Immucor is a Private company.
-
What is the current valuation of Immucor?
The current valuation of Immucor is .
-
What is Immucor’s current revenue?
The current revenue for Immucor is .
-
How much funding has Immucor raised over time?
Immucor has raised $664M.
-
Who are Immucor’s investors?
TPG, The Riverside Company, and ValueAct Capital Management have invested in Immucor.
-
Who are Immucor’s competitors?
DexCom, Biotronik, ELITechGroup, Genalyte, and Baxter International are some of the 14 competitors of Immucor.
-
When was Immucor acquired?
Immucor was acquired on 15-Mar-2023.
-
Who acquired Immucor?
Immucor was acquired by Werfen (Spain).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
